TLX vs RNW

For growth investors, Telix Pharmaceuticals Limited (TLX) is the stronger pick with 55.

8% revenue growth year-over-year, versus 19. 4% for ReNew Energy Global Plc (RNW). ReNew Energy Global Plc (RNW) offers the better valuation at 46. 9x trailing P/E (0. 4x forward), making it the more compelling value choice. Analysts rate Telix Pharmaceuticals Limited (TLX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ReNew Energy Global Plc (RNW) is the cheapest at 46.

9x versus Telix Pharmaceuticals Limited at 105. 1x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x.

Over the past 5 years, Telix Pharmaceuticals Limited (TLX) delivered a total return of -29.

6%, compared to -45. 7% for ReNew Energy Global Plc (RNW). Over 10 years, the gap is even starker: TLX returned -29. 6% versus RNW's -50. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ReNew Energy Global Plc (RNW) is the lower-risk stock at 0.

62β versus Telix Pharmaceuticals Limited's 0. 89β — meaning TLX is approximately 42% more volatile than RNW relative to the S&P 500. On balance sheet safety, Telix Pharmaceuticals Limited (TLX) carries a lower debt/equity ratio of 102% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Telix Pharmaceuticals Limited (TLX) is pulling ahead at 55.

8% versus 19. 4% for ReNew Energy Global Plc (RNW). On earnings-per-share growth, the picture is similar: Telix Pharmaceuticals Limited grew EPS 769. 6% year-over-year, compared to 10. 1% for ReNew Energy Global Plc. Over a 3-year CAGR, TLX leads at 368. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Telix Pharmaceuticals Limited (TLX) is the more profitable company, earning 6.

4% net margin versus 3. 9% for ReNew Energy Global Plc — meaning it keeps 6. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus 10. 5% for TLX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.

4x forward P/E versus 168. 7x for Telix Pharmaceuticals Limited — 168. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TLX: 59. 5% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ReNew Energy Global Plc (RNW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

62)). Both have compounded well over 10 years (RNW: -50. 5%, TLX: -29. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TLX (Healthcare) and RNW (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.